Health
Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer Subgroup – Cancer Network
Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr…
Second-line treatment with nivolumab (Opdivo) plus paclitaxel showed clinical activity and a manageable safety profile in patients with Epstein-Barr virusrelated, microsatellite instabilityhigh (MSI-H)/mismatch repair deficient (dMMR) or PD-L1positive advanced gastric cancer, according to findings from a phase 1/2 study (NCT02951091) presented during Week 1 of the virtual AACR Annual Meeting 2021.1
At a median follow-up of 10.8 months, data from the phase 2 cohort (n = 48) showed that the combination…
Continue Reading
